Point72 Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Point72 Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-167	Closed	-$6.75K	–	2202
2023 Q3	$6.75K	Sell	167 -14,955	-99%	-$1.51M	﹤0.01%	2346
2023 Q2	$1.61M	Buy	+15,122	New	+$5.04M	﹤0.01%	1073
2022 Q2	–	Sell	-5,056	Closed	-$1.69M	–	1412
2022 Q1	$1.69M	Buy	+5,056	New	+$1.47M	0.01%	897
2020 Q1	–	Sell	-15,938	Closed	-$3.73M	–	793
2019 Q4	$3.73M	Buy	15,938 +2,813	+21%	+$283K	0.02%	534
2019 Q3	$1.48M	Buy	+13,125	New	+$2.07M	0.01%	632
2018 Q4	–	Sell	-1,191	Closed	-$146K	–	974
2018 Q3	$146K	Sell	1,191 -2,922	-71%	-$434K	﹤0.01%	962
2018 Q2	$605K	Buy	4,113 +397	+11%	+$60.6K	﹤0.01%	867
2018 Q1	$609K	Buy	+3,716	New	+$620K	﹤0.01%	845

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 Asset Management's BTAI Position: Q4 2023 in Review

Point72 Asset Management sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 167 shares — an estimated $6.75K sold.

Point72 Asset Management first reported a position in BTAI in Q1 2018 and held it in 8 quarters. The position peaked at $3.73M in Q4 2019. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

Point72 Asset Management reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
Point72 Asset Management sold 167 BioXcel Therapeutics shares in Q4 2023, an estimated $6.75K.
Point72 Asset Management first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 8 quarters.
Point72 Asset Management's BioXcel Therapeutics position peaked at $3.73M in Q4 2019.
73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.